



G1 Therapeutics to Participate in Two Upcoming Conferences

November 10, 2021

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences.

- On November 17, 2021 at 8:00 AM EST, G1's Chief Executive Officer Jack Bailey will present at the Stifel 2021 Virtual Healthcare Conference.
- On December 1, 2021 at 12:35 PM EST, Mr. Bailey will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference.

The webcast of both events will be accessible on the [Events & Presentations page](http://www.g1therapeutics.com) of <http://www.g1therapeutics.com>.

About G1 Therapeutics

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating trilaciclib in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter [@G1Therapeutics](https://twitter.com/G1Therapeutics).

Contacts:

Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com



Source: G1 Therapeutics